Skip to main content
SpringerLink
Log in

Maraviroc: a guide to its use in HIV-1 infection

  • Drug and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Carter N, Keating GM. Maraviroc. Drugs 2007; 67(15): 2277–88

    Article  PubMed  CAS  Google Scholar 

  2. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005 Nov; 49(11): 4721–32

    Article  PubMed  CAS  Google Scholar 

  3. European Medicines Agency. Celsentri: summary of product characteristics [online]. Available from URL: http://emea.europa.eu [Accessed 2007 Dec 7]

  4. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006 May; 80(10): 4909–20

    Article  PubMed  CAS  Google Scholar 

  5. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results from a phase 2b/3 study in the US and Canada [abstract no. 104bLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)

  6. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results [abstract no. 104aLB plus oral presentation]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25–28; Los Angeles (CA)

  7. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase 3 studies MOTIVATE 1 and MOTIVATE 2 originates from a pre-existing minority of CXCR4-using virus [abstract no. 56 plus poster and oral presentation]. XVI International HIV Drug Resistance Workshop; 2007 Jun 12–16; Barbados

  8. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagnoist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007 Mar; 81(5): 2359–71

    Article  PubMed  CAS  Google Scholar 

  9. Selzentry™ (maraviroc tablets): US prescribing information. New York: Pfizer Inc., 2007 Aug

    Google Scholar 

  10. Lalezari J, Mayer H. Efficacy and safety of maraviroc in antiretroviral treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1 [abstract no. H-718a]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Chicago (IL)

  11. Proestel S. FDA analyses of maraviroc safety data [online]. Available from URL: http://www.fda.gov [Accessed 2007 Jul 23]

  12. FDA Maraviroc Review Team. FDA cover memorandum [online]. Available from URL: http://www.fda.gov [Accessed 2007 Apr 25]

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maraviroc: a guide to its use in HIV-1 infection. Drugs Ther. Perspect 24, 1–4 (2008). https://doi.org/10.2165/00042310-200824030-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824030-00001

Keywords

Search

Navigation